Can DNA Testing Tell Identical Twins on Trial Apart?

Why It Matters

The inability to separate twins with conventional DNA tests threatens the reliability of forensic evidence and could prompt courts to demand more advanced, expensive genomic analyses, driving demand for specialized sequencing services. This shift may reshape forensic market dynamics and raise privacy and cost considerations for law‑enforcement agencies.

Key Takeaways

• Conventional STR analysis cannot differentiate monozygotic twins
• Whole-genome sequencing can reveal post‑zygotic mutations
• Mitochondrial DNA mutates faster, offering another distinction method
• DNA methylation patterns differentiate most twin pairs in studies
• Sample quantity, cost, and legal admissibility hinder forensic use

Pulse Analysis

Forensic identification has relied on short‑tandem‑repeat (STR) profiling for decades, amplifying a handful of highly variable loci to match crime‑scene DNA with suspects. The technique is fast, inexpensive, and works well for unrelated individuals, but it collapses when the sample belongs to monozygotic twins, whose nuclear genomes are virtually identical. The recent French trial, where DNA on a firearm matched both brothers, illustrates this blind spot and raises questions about the evidentiary weight of standard DNA tests in complex cases. The case also spotlights the growing reliance on DNA as the cornerstone of modern criminal investigations.

Scientists are turning to whole‑genome sequencing, mitochondrial DNA (mtDNA) profiling, and epigenetic methylation signatures to break the twin impasse. Whole‑genome approaches can capture rare post‑zygotic mutations—sometimes only a handful per twin pair—providing a unique genetic fingerprint. mtDNA, which mutates more rapidly than nuclear DNA, has already been admitted in U.S. courts and can differentiate twins when nuclear markers fail. Recent Korean studies also demonstrated that a small panel of methylation sites correctly distinguished up to 90 % of adult twin pairs, suggesting a scalable forensic tool. These techniques also open possibilities for cold‑case resolutions where traditional STR profiles were inconclusive.

Despite their promise, these advanced methods face practical and legal hurdles. Crime‑scene samples are often degraded or limited, making the high DNA input requirements of whole‑genome and mtDNA sequencing problematic. The analytical pipelines are expensive, time‑consuming, and require expert interpretation, which can strain public‑sector budgets. Moreover, courts demand rigorous validation before admitting novel genomic evidence, a process that can take years. Regulatory bodies are beginning to draft guidelines to standardize reporting and ensure reproducibility across labs. As forensic laboratories adopt these technologies, vendors of next‑generation sequencing platforms and bio‑informatics services are likely to see increased demand, reshaping the forensic market landscape.